Marinus Pharmaceuticals Quote - MRNS

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Current Price

0.3299

Bid

0.318

Offer

0.33

Volume

867,732

0.312 Day's Range 0.34

0.2603 52 Week Range 11.26

Market Cap

18.206M

Previous Close

0.3223

Open

0.3223

Last Trade

0.3228

Last Trade Time

Financial Volume

US$ 280,888

VWAP

0.323704

Average Volume (3m)

2,633,346

Shares Outstanding

55,185,622

Dividend Yield

PE Ratio

-0.12

Earnings Per Share (EPS)

-2.56

Revenue

30.99M

Net Profit

-141.41M

Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychi... Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19 pediatric epilepsy. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.marinuspharma.com

Headquarters

Wilmington, Delaware, USA

Founded

Marinus Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker MRNS. The last closing price for Marinus Pharmaceuticals was US$0.32. Over the last year, Marinus Pharmaceuticals shares have traded in a share price range of US$ 0.2603 to US$ 11.26.

Marinus Pharmaceuticals currently has 55,185,622 shares in issue. The market capitalisation of Marinus Pharmaceuticals is US$17.79 million. Marinus Pharmaceuticals has a price to earnings ratio (PE ratio) of -0.12.

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.0299	9.96666666667	0.3	0.33	0.2912	1023397	0.30864206	CS
4	0.0298	9.93002332556	0.3001	0.46	0.2603	4227229	0.36710829	CS
12	-1.1001	-76.9300699301	1.43	1.97	0.2603	2633346	0.54374228	CS
26	-1.0001	-75.1954887218	1.33	1.97	0.2603	1638962	0.75115697	CS
52	-5.6601	-94.4924874791	5.99	11.26	0.2603	1425928	1.95571073	CS
156	-11.8901	-97.3003273322	12.22	13.15	0.2603	787911	4.14981205	CS
260	-0.7301	-68.8773584906	1.06	20.04	0.2603	1085614	4.18666378	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
PDYNPalladyne AI Corporation	US$ 4.59 (129.50%)	83M
QMCOQuantum Corporation	US$ 9.11 (126.62%)	39.41M
NANano Labs Ltd	US$ 8.26 (89.02%)	2.03M
XCURExicure Inc	US$ 18.60 (71.27%)	4.36M
SKKSKK Holdings Limited	US$ 1.75 (59.09%)	95.06M
AMIXAutonomix Medical Inc	US$ 6.21 (-54.07%)	897.51k
CETXCemtrex Inc	US$ 0.1146 (-41.74%)	22.89M
MSWMing Shing Group Holdings Ltd	5.90 (-35.52%)	417.08k
RMSGReal Messenger Corporation	US$ 3.09 (-26.25%)	305.85k
ENSCEnsysce Biosciences Inc	US$ 0.4414 (-25.49%)	3.93M
ELABElevai Labs Inc	US$ 0.0201 (-0.50%)	415.87M
NVDANVIDIA Corporation	US$ 141.95 (-3.22%)	229.93M
SMCISuper Micro Computer Inc	US$ 33.15 (11.62%)	155.43M
VRPXVirpax Pharmaceuticals Inc	US$ 0.5501 (-6.72%)	154.17M
SOUNSoundHound AI Inc	US$ 8.24 (18.05%)	103.6M